ALX Oncology (ALXO) Corporate presentation summary

Pipeline overview and strategy

• Advancing two novel cancer therapies: evorpacept (CD47 blocker) and ALX2004 (EGFR ADC), both with differentiated designs and promising early data.

• Evorpacept is being tested in multiple combinations and indications, including breast cancer, gastric cancer, and lymphoma.

• ALX2004 is in Phase 1 dose escalation for EGFR-expressing solid tumors, with preclinical data supporting its safety and efficacy.

• Multiple clinical milestones are anticipated in 2026–2027, including topline data for breast cancer and safety data for ALX2004.

• Projected cash runway extends through the first half of 2028, supported by recent $150M financing.

Evorpacept clinical highlights

• Evorpacept’s inactive Fc design minimizes toxicity compared to conventional CD47 blockers.

• Demonstrated robust clinical activity and tolerability in combination with anti-cancer antibodies across several trials.

• In HER2+ gastric cancer, addition of evorpacept improved ORR, duration of response, and progression-free survival, especially in CD47-high patients.

• CD47 expression serves as a predictive biomarker for response, validated in both gastric and breast cancer studies.

• Manageable safety profile observed in over 750 patients, with adverse events comparable to control arms.

ALX2004 preclinical and clinical development

• ALX2004 is an EGFR-targeted ADC with a proprietary linker-payload and matuzumab-derived antibody for improved safety.

• Preclinical studies show potent, dose-dependent anti-tumor activity across multiple tumor types and EGFR mutations.

• Superior bystander effect and tumor targeting compared to deruxtecan ADCs in mouse models.

• Non-human primate studies indicate no dose-limiting toxicities or interstitial lung disease at clinically relevant doses.

• Phase 1 trial is enrolling patients with EGFR-expressing tumors, with safety data expected in 2H 2026.